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Abstract
Pulmonary hypertension (PH) is a complex disease comprising a pathologic
remodeling and thickening of the pulmonary vessels causing an after load on
the right heart ventricle that can result in ventricular failure. Triggered by
oxidative stress, episodes of hypoxia, and other undetermined causes, PH is
associated with poor outcomes and a high rate of morbidity. In the neonate,
this disease has a similar etiology but is further complicated by the transition
to breathing after birth, which requires a reduction in vascular resistance. Per-
sistent pulmonary hypertension of the newborn (PPHN) is one form of PH
that is frequently unresponsive to current therapies including inhaled nitric
oxide (due to lack of proper absorption and diffusion), and other therapeutics
targeting signaling mediators in vascular endothelium and smooth muscle.
The need for novel agents, which target distinct pathways in pulmonary
hypertension, remains. Herein, we investigated the therapeutic effects of novel
muscarinic receptor ligand C1213 in models of PH. We demonstrated that via
M3 muscarinic receptors, C1213 induced activating- eNOS phosphorylation
(serine-1177), which is known to lead to nitric oxide (NO) production in
endothelial cells. Using signaling pathway inhibitors, we discovered that AKT
and calcium signaling contributed to eNOS phosphorylation induced by
C1213. As expected for an eNOS-stimulating agent, in ex vivo and in vivo
models, C1213 triggered pulmonary vasodilation and induced both pulmonary
artery and systemic blood pressure reductions demonstrating its potential
value in PH and PPHN. In brief, this proof-of-concept study provides evi-
dence that an M3 muscarinic receptor functionally selective ligand stimulates
downstream pathways leading to antihypertensive effects using in vitro,
ex vivo, and in vivo models of PH.
Introduction
Pulmonary hypertension (PH) is a chronic debilitating dis-
ease that elicits vascular remodeling, progressive hypox-
emia, and right ventricular heart failure. Hypoxia leads to
pulmonary vessel constriction, and persistent hypoxia
causes uncontrolled proliferation of endothelial cells,
smooth muscle cells (SMC), and adventitial fibroblasts.
Each of these sequelae contribute to pulmonary vascular
remodeling (vessel narrowing), which in turn chronically
increases resistance to blood flow through the pulmonary
circulation, leading to right ventricular failure and declin-
ing cardiac output.(Leopold and Maron 2016).
Vascular endothelial and smooth muscle cell interac-
tions and downstream signaling pathways, including
those induced by acetylcholine receptors (muscarinic),
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adrenergic receptors (Faber et al. 2007), and nitric oxide
(NO) (Kysela and Torok 2000), are among the factors
that are crucial to the regulation of vascular tone and
therefore serve as therapeutic targets for interference
with PH development and progression. Persistent pul-
monary hypertension of the newborn (PPHN) is a dis-
ease characterized by resistance to therapies with a high
rate of morbidity and mortality. The only currently
FDA-approved treatment for PPHN is inhaled NO
(iNO) to which one third of patients may be resistant.
Although other off-label usage drugs are employed,
including oral pulmonary vasodilators and phosphodi-
esterase inhibitors, there are not yet enough clinical
studies to fully evaluate their safety and effectiveness
(Lakshminrusimha et al., 2016a), leaving the search for
agents which improve PH in the newborn an imperative
and open field. Agents which stimulate endogenous NO
production are also an intriguing avenue for treatment,
as the release of NO from endothelial cells is known to
activate soluble guanylate cyclase (sGC) in vascular
smooth muscle cells which, through cyclic GMP produc-
tion (cGMP) and Ca+2 efflux, leads to pulmonary
vasodilatory responses (reviewed in (Tonelli et al. 2013;
Quillon et al. 2015)). We began our project by searching
our chemical library for agents that enhanced eNOS
phosphorylation as this provided a surrogate measure of
localized endogenous NO production. This screen
resulted in the discovery of compound 1213.
Compound 1213 (C1213) is a tetravalent guanylhydra-
zone (Fig. 1A) which has been independently tested and
shown to bind neurohumoral transmitter receptors
including adrenergic receptors (a1 nonselective
Kd = 2 9 10
10, a2 nonselective Kd = 1.5 9 10
9), dopa-
mine receptors (D1 Kd = 1 9 10
9, D2 Kd = 7 9 10
10),
opioid receptors (nonselective Kd = 2 9 10
9, ORL-1
Kd = 5 9 10
10), a serotonin transporter (Kd = 1.7 9
109), a histamine receptor (H2 Kd = 7 9 10
10), and
muscarinic receptors (nonselective Kd = 1 9 10
10).
More specific testing for functional agonism and antago-
nism was then carried out for the muscarinic acetyl-
choline receptors as they are known to play crucial roles
in pulmonary artery vasoconstriction/vasodilation (Orii
et al. 2010; Harvey 2012), with species-specific differences
noted (Walch et al. 1999). M3 muscarinic receptors are
prevalent in both pulmonary vascular smooth muscle
(Walch et al. 2001), and have been shown to mediate pul-
monary artery vasodilatory responses to acetylcholine in
an ex vivo model (Orii et al. 2010). In this report we set
out to determine the effect of C1213 in in vitro, ex vivo,
and in vivo PH and PPHN models. An agent that stimu-
lates endogenous NO production, with functionally selec-
tive activity on muscarinic receptors could provide a
unique means to interfere with PH-driven pathologies.
Material and Methods
All animal studies were performed in accordance with
accepted guidelines and IACUC requirements. Data sig-
nificance was measured using successive t-tests with a P-
value of 0.05 as a cutoff. All chemicals and reagents were
acquired from Sigma-Aldrich (St. Louis, MO) or indi-
cated vendors. Compound 1213 was synthesized by Dr.
Al-Abed and was ≥95% pure by HPLC and structure was
confirmed by MS and NMR (structure illustrated in
Fig. 1). Cell-line HPMEC-ST1.6R was negative for myco-
plasma contamination upon receipt.
In vitro endothelial cell studies
Neurotransmitter/neurohumoral receptor assays
Binding (Kd’s), and functional agonist, and antagonist
(calcium mobilization) assays were performed by NovaSc-
reen Biosciences (currently part of Caliper-Perkin Elmer,
Hopkinton, MA) as a fee for service by standardized pro-
tocols using cell lines overexpressing respective receptors
under investigation.
Endothelial cell culture and hypoxia exposure
The human pulmonary microvascular endothelial cell line,
HPMEC-ST1.6R, was kindly provided by C. James Kirk-
patrick, Institute of Pathology, Johannes-Gutenberg
University, Germany. This cell line was generated by
cotransfection with pSV3neo and pC1.neo.hTERT
(Krump-Konvalinkova et al. 2001). At least 99% of cells
were endothelial cells as evidenced by staining for
platelet endothelial cell adhesion molecule (PECAM-1,
CD31), von Willebrand factor (vWF), and the adhesion
molecules, intercellular adhesion molecule (ICAM-1), vas-
cular adhesion molecule (VCAM-1), and E-selectin. In
addition, HPMEC-ST1.6R showed an angiogenic response
on Matrigel similar to that of primary HPMEC and was
not tumorgenic in nude mice (Krump-Konvalinkova et al.
2001). Endothelial cells (ECs) were cultured using
Endothelial Cell Growth Medium (C22020 Heidelberg,
Germany) under 5% CO2 at 37°C. Media was changed
every second day. Hypoxia was created by flushing the
chamber with 95% Nitrogen and 5% CO2 gas mixture.
Cells were incubated under hypoxia for 1 h.
endothelial Nitric Oxide Synthetase (eNOS)
phosphorylation assay
Compound 1213 was added to EC culture immediately
before hypoxia exposure. One hour later, phosphorylation
of serine-1177 endothelial nitric oxide synthetase (eNOS)
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was measured by Western blot in both ECs incubated in
room air (RA) or exposed to hypoxia. Commercially
available antibodies for serine-1177 PO4 eNOS, total
eNOS (Cell Signaling Technologies Danver, MA), and sec-
ondary antibodies (Santa Cruz Biotechnologies, Santa
Cruz, CA) were used. Cells were washed with ice-cold
PBS twice and were immediately lysed in the plate using
RIPA buffer supplemented with protease and phosphatase
inhibitor cocktail (Roche Applied Science, Indianapolis,
IN). Proteins were resolved on SDS-PAGE and blotted on
PVDF membrane. Beta-actin (Ab from Genscript, Piscat-
away, NJ) was used as a loading control for normaliza-
tion. Different doses of C1213 were used to assess target
dose in relation to maximum physiological function and
10 lM was selected for studies. Densitometry was per-
formed using Image J software which is freely available at
https://imagej.nih.gov/ij/index.html. cGMP as a product
of NO production was also assayed in EC culture cells
after treating them with vehicle or C1213 (ELIZA assay,
Cayman, Ann Arbor, Michigan).
Acetylcholine receptor blockade study
We used a series of acetylcholine receptor blockers and
measured (serine-1177) phosphorylated eNOS protein
(normalized to actin) as a read out. Both C1213
(10 lmol/L) and indicated blockers (antagonists) were
added to EC tissue culture and the western experiment
described above was repeated. The following receptor
antagonists were used: Atropine at dose of 0.01 lmol/L
was used as nonspecific muscarinic (M) receptor block-
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Figure 1. (A) Two- and three-dimensional structure rendering of C1213 generated using Chemdraw Ultra (version 12.0.3.1216) and Molecular
Operating Environment (version 2015.10). (B) Agonist-binding displacement studies (functional antagonism) in Novascreen cells (Caliper-Perkin
Elmer) overexpressing muscarinic receptors. IC-50 values are shown for C1213 versus no-specific muscarinic antagonist atropine. (C)
Phosphorylated eNOS protein expression normalized to total eNOS in HPMEC-ST1.6R cells exposed to normal or hypoxic conditions and vehicle
versus C1213 at 10 lM. Experiment was repeated 39 on different days and representative blots are shown for indicated treatment/staining.
* P < 0.05 compared with vehicle control. (D) cGMP expression in HPMEC-ST1.6R cells exposed to vehicle versus C1213. * P < 0.05 compared
with vehicle control.
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100 lmol/L; dareifenacin (M3 blocker) at doses 0.01, 0.1,
and 1 lmol/L, and methyllycaconitine (MLA) nicotinic
blocker at doses 0.1, 1, and 10 lmol/L. Pirenzepine dihy-
drochloride was purchased from Tocris Bioscience (Bris-
tol, UK).
Signaling pathway studies
To investigate downstream signaling events, the following
kinase inhibitors were employed: wortmannin (upstream
inhibitor of Akt), dorsomorphin dihydrochloride aka
“compound C” (AMPK inhibitor), and BAPTA-AM
(Ca+2 chelator). Wortmannin, compound C, and
BAPTA-AM were purchased from Tocris Bioscience (Bris-
tol, UK). Western blot for AKT, pAKT, and actin was
performed as described above. Commercially available
primary antibodies for AKT, pAKT, and secondary anti-
bodies were used in westerns (Santa Cruz Biotechnologies,
Santa Cruz, CA).
Ex vivo pulmonary artery studies
Physiological function assessments were performed on
explanted main intralobar pulmonary arteries with intact
endotheliumas previously described in mice (Ahmed et al.
2012). The pulmonary arterial rings (experiments were
repeated five times using five rings) were contracted with
increasing cumulative doses of phenylephrine (PE) (1, 10,
and 100 nmol/L) doses followed by relaxation with
increasing doses of acetylcholine (Ach) (10 nmol/L,
100 nmol/L, 1 mmol/L, and 10 mmol/L) (Ach–8 to Ach–
5). Arteries were again reequilibrated with normal Krebs-
bicarbonate buffer for another 30 min and then were
contracted with 100 nmol/L phenylephrine followed by a
dose of C1213 compound (10 lM).
In vivo studies—PPNH model
This study was approved by the Laboratory Animal Care
Committee at the State University of New York (SUNY)
Buffalo. Fetal ductal ligation was performed 20 days pre-
term at 125 days of gestation (n = 2) in time-dated preg-
nant sheep (Morin 1989). After a 9-d recovery, lambs
with PPHN were delivered by cesarean section. Alive
lambs were intubated, and standard of care equivalent for
human neonates was followed (Lakshminrusimha et al.
2006). Thoracotomy and instrumentation of the pul-
monary arteries (PA) was achieved and oxygenation was
measured as arterial-to-alveolar oxygen ratios: a/A
ratio = umbilical arterial PaO2/[745 - 47] X FiO2 -
PaCO2/0.8, where 745 mmHg is the barometric pressure
at Buffalo, and 47 mmHg is the partial pressure of water.
Pulmonary vascular resistance (PVR) was calculated using
the following equation: PVR (mmHg.mL1.min.kg body
weight) = (mean PA pressure-left atrial pressure in mm
Hg) 47 pulmonary blood flow corrected for body weight
(Qp, mL.min
1 kg1). Systemic and pulmonary pressure,
pulmonary and coronary blood flow, PaO2, and PaCO2
were recorded and once the animal was stable (about 2 h
post partum), an IV bolus dose of 1213 (4 mg/kg –
approx. 80 lmol/L in blood max.) was given. Readings of
systemic and pulmonary vascular pressure and PO2/PCO2
were monitored postinjection of C1213.
Statistical analysis
Statistical evaluation of eNOS expression using different
blockers was performed using the Analysis of Variance
test (ANOVA). T-test was used in comparison between
two groups. A P-value of less than 0.05 is considered to
be significant. Statistical software SPSS Version 17 and
MS Excel were used to analyze the data.
Results
C1213 Functional receptor activation studies
Neurohumoral/neurotransmitter receptor functional acti-
vation was explored using a Novascreen G-protein cou-
pled receptor (GPCR) calcium flux assay (Caliper- Perkin
Elmer, Hopkinton, MA). For agonist studies, C1213 (2D
and 3D structure shown in Fig. 1A) was added at a range
of doses and Ca+2 mobilization was measured. No ago-
nistic activity was observed for the receptors studied (data
not shown) at lower doses of compound (nanomolar
range). At the highest two concentrations tested (5 and
10 lmol/L) in cells overexpressing certain receptors,
C1213 induced nonspecific calcium flux through an
unelucidated mechanism of action. This finding is diffi-
cult to interpret as these cells are engineered (proprietary)
to stimulate calcium release as a readout of GPCR activa-
tion and also express much higher levels of receptors than
a native cell, alternatively, compound solubility issues in
the specialized buffer may have been the cause.
For functional antagonism studies, we found that
C1213 was able to inhibit agonist (acetylcholine) stimula-
tion of calcium flux for muscarinic receptors M1, M2,
and M3, with IC-50’s shown in Figure 1B compared with
nonspecific muscarinic antagonist atropine.
Effect of C1213 in hypoxia versus room air
Our data demonstrated that hypoxia led to an increase in
the serine-1177 eNOS phosphorylation as expected. Addi-
tion of C1213 for 1 h elicited a significant induction of
ser-1177 eNOS phosphorylation in the endothelial cell-
2016 | Vol. 4 | Iss. 24 | e13069
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line HPMEC-ST1.6R in both normal (room air, FiO2
21%) and hypoxic (FiO2 1% for 60 min) conditions
(Fig. 1C). To support our findings, cGMP was also mea-
sured and showed marked significant increase in NO pro-
duction and its bioavailability, marked by significant
increase in cGMP in treated EC culture with C1213
(Fig. 1D). These data strongly suggest that C1213 will
meaningfully augment endogenous NO production (Bar-
auna et al. 2013; Tonelli et al. 2013).
Acetylcholine receptor antagonism studies in
pulmonary endothelial cells
These studies investigate the specific neurohumoral recep-
tor subtype responsible for C1213 effects on serine-1177
eNOS phosphorylation, which is a known stimulator of
eNOS activity (Kolluru et al. 2010). In standard condi-
tions, C1213 significantly increased the relative abundance
of phosphorylated eNOS protein compared with total
eNOS (Fig. 2). In contrast, the coaddition of atropine (a
nonspecific competitive antagonist of muscarinic recep-
tors) essentially blocked the 1213-mediated increase in
phosphorylated eNOS. As atropine acts on all muscarinic
receptors (M1 through M5), we next used more specific
receptor antagonists. Coaddition of pirenzepine (an M1
blocker) did not impact C1213 activity, whereas dareife-
nacin (a specific M3 blocker) markedly reduced C1213-
mediated eNOS phosphorylation (Fig. 2). In a control
experiment, coaddition of methyllycaconitine (MLA, a
nicotinic acetylcholine receptor blocker that does not
exert its effects through muscarinic receptors) caused no
meaningful change in eNOS phosphorylation (Fig. 2).
Taken together, these findings suggest that C1213 will
stimulate endogenous NO production through eNOS acti-
vation in pulmonary vascular endothelial cells and this
stimulation is mediated specifically through M3 mus-
carinic receptors.
Downstream signaling studies
Protein kinases (AKT and AMPK) activate NO produc-
tion through phosphorylation of eNOS at specific amino
acid residues. We investigated the functional involvement
of AKT- and AMPK-dependent and -independent path-
ways in C1213-induced eNOS phosphorylation (ser-1177)
by looking at cell lysates of pulmonary endothelial cell
cultures treated with C1213 for 1 h, in the presence and
absence of various kinase inhibitors. When coincubated
with wortmannin (AKT inhibitor) or BAPTA (Ca+2
chelator), eNOS phosphorylation was dampened, how-
ever, compound C (AMPK inhibitor) had no effect
(Fig. 3A). The relative downregulation of eNOS phospho-
rylation in the presence of these kinase inhibitors suggests
that C1213 mediates eNOS phosphorylation by activating
AKT and/or through Ca+2-dependent means (likely via
CaMKII) (Fig. 3A) (P < 0.05; ANOVA; comparing effect
of each blocker to vehicle and 1213 compound on p-
eNOS/eNOS ratio). We next examined the effect of
C1213 on AKT activation by assessing its phosphorylation
state in the presence of the same kinase inhibitors. When





































+     +     +     +     +     +     +     +     +     +     +   + Vehicle
+     +     +     +     +     +     +     +     +     +     +    C1213 (10 µmol/L)
+                   Atropine (0.01 µmol/L)
+    +     +              Pirenzepine (1,10,100 µmol/L)
+     +     +                         Dareifenacin (0.01, 0.1, 1 µmol/L)
+     +     + MLA (0.1, 1, 10 µmol/L)
*ANOVA: comparison between the 3 blockers at each relevant conc. and the 1213 compound , P < 0.05)
Figure 2. Total eNOS normalized phosphorylated eNOS expression in HPMEC-ST1.6R cells exposed to acetylcholine receptor blockers at doses
sequentially indicated. Experiment was repeated 59 on different days and representative blots are shown for indicated treatments/staining.
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2016 | Vol. 4 | Iss. 24 | e13069
Page 5
M. Ahmed et al. Effects of M3R Ligand C1213 in PH Models
normalized to total AKT, C1213 induced AKT phospho-
rylation and as anticipated, only wortmannin profoundly
inhibited AKT phosphorylation (Fig. 3A, lower panel)
(ANOVA test; P < 0.05). Taken together, these finding
begin to decipher pathways by which C1213 stimulates
NO production: it increases the phosphorylation and acti-
vation of eNOS mainly through AKT and Ca+2 signaling
mechanisms, but not through AMPK.
Ex vivo studies
In our mice studies of explanted PA vessels with endothe-
lium, we found that C1213 (10 lmol/L) rapidly (within
2 min) overcame the contraction induced by PE and the
tone essentially dropped to the pre-PE baseline level
within 1–2 min (Fig. 3B). Thus, C1213 rapidly relaxes
contracted pulmonary vasculature when compared with
vehicle control.
In vivo studies
For our studies we used the gold standard model of
PPHN in lambs, where PH is induced by ductal ligation
in utero. The success of our model of PPHN was demon-
strated by a peak PA pressure of close to 40 mmHg (a
normal range for PA pressure is 15–20 mmHg). In the
initial phase of monitoring, systemic and PA pressures
and ventilation status were stabilized allowing for accli-
mation (Fig. 3C—plateau). Systemic (IV) administration
of C1213 induced a marked (~25%) drop in both PA and
systemic (systolic and diastolic) pressures (Fig. 3C—post-
C1213 dashed vertical line). Effects of C1213 on oxygena-
tion and ventilation are also of note. Administration of
C1213 induced an increase in PaCO2 and complementary
decrease in PaO2. At 114 min, this pattern was reversed:
PaCO2 precipitously fell and PaO2 precipitously rose.
These changes were likely governed by the C1213-
Figure 3. (A) Phospho-protein expression normalized in HPMEC-ST1.6R cells exposed to kinase inhibitors and calcium blocker (top panel—
normalized to eNOS; bottom panel—normalized to AKT). Experiment was repeated 39 on different days and representative blots are shown
for indicated treatments/staining. ANOVA was used to compare effect of each individual blocker, vehicle, and 1213 compound in expression of
p-eNOS or p-AKT; * P < 0.05. (B) Vascular contraction studies in excised murine endothelium-associated pulmonary arteries. After arteries were
tested for responses, baseline was stabilized and phenylephrine was infused (22 min), followed by C1213 (top panel—blue trace) or vehicle
(bottom panel—green trace) at 25 min (n = 5 arterial rings). (C) Systemic and pulmonary artery blood pressure responses to C1213 infusion
(dashed vertical line) of 4 mg/kg in neonatal hypertension model (N = 2 animals).
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mediated decrease in PA flow. Focusing on the critical
variable of oxygenation, C1213 causes the mean PA pres-
sure to fall, when it goes below ~30 mmHg (which takes
~40 min) a rapid reflexive increase in PaO2 and corre-
sponding decrease in PaCO2 is elicited which then nor-
malizes.
Discussion
Although O2 and NO inhalation therapy remains some of
the most effective treatments for PPHN, this research has
revealed the risks of oxidative stress that can be induced
by inhaled oxygen (and potentially iNO) therapies (re-
viewed in [Lakshminrusimha et al., 2016b]). Evidence that
oxidative stress is a crucial factor in PPHN (Afolayan et al.
2012, 2016), as well as cases refractory to iNO therapy,
provided the basis for our search for more moderate ways
to stimulate the endogenous NO response (EC eNOS>-
NO>SMC sGC>cGMP>Ca+2 > SMC relaxation) as a
means to modulate PPHN. A screen for eNOS activators
(serine-1177 PO4) lead to the discovery of C1213, which
was found to act as a functionally selective agonist on M3
receptors of pulmonary vascular endothelial cells. A sum-
mary of our main findings in endothelial cells and ex vivo
and in vivo models of PPHN is presented in Figure 4.
Combined, our results provide evidence for the contin-
ued investigation of C1213 as a new experimental
vasodilatory agent, capable of stimulating endogenous
NO production from endothelial vascular cells, leading to
relaxation of smooth muscle pulmonary vasculature, and
reduction in pulmonary hypertension. Additional testing
indicated that C1213 may act as either a competitive
antagonist or functionally selective agonist on muscarinic
receptors, which was dependent on the downstream assay
monitored and/or cell type used for study. Future studies
will look at larger sample size of animal model with
PPHN and look at the longer-term effects of C1213
administration and help clarify other potential mecha-
nisms (modulation of other neurohormonal receptors or
mediators) by which C1213 generates its effects on pul-
monary arterial and systemic vascular pressure.
Acknowledgments




Afolayan, A. J., A. Eis, R. J. Teng, I. Bakhutashvili, S. Kaul, J.
M. Davis, et al. 2012. Decreases in manganese superoxide
dismutase expression and activity contribute to oxidative
stress in persistent pulmonary hypertension of the newborn.
Am. J. Physiol. Lung Cell. Mol. Physiol. 303:L870–L879.
Afolayan, A. J., A. Eis, M. Alexander, T. Michalkiewicz, R. J.
Teng, S. Lakshminrusimha, et al. 2016. Decreased
endothelial nitric oxide synthase expression and function
contribute to impaired mitochondrial biogenesis and
oxidative stress in fetal lambs with persistent pulmonary
hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 310:
L40–L49.
Ahmed, M. N., Y. Zhang, C. Codipilly, N. Zaghloul, D. Patel,
M. Wolin, et al. 2012. Extracellular superoxide dismutase
overexpression can reverse the course of hypoxia-induced
pulmonary hypertension. Mol. Med. 18:38–46.
Barauna, V. G., P. R. Mantuan, F. C. Magalhaes, L. C. Campos,
and J. E. Krieger. 2013. AT1 receptor blocker potentiates
shear-stress induced nitric oxide production via modulation
of eNOS phosphorylation of residues Thr(495) and Ser
(1177). Biochem. Biophys. Res. Commun. 441:713–719.
Faber, J. E., C. L. Szymeczek, S. Cotecchia, S. A. Thomas, A.
Tanoue, G. Tsujimoto, et al. 2007. Alpha1-adrenoceptor-














Pulmonary vasodilation (ex vivo mice vessels)
cGMP
PA and systemic BP decrease , PCO2 decrease, PO2 increase
(in vivo neonatal PH model)
Figure 4. Summary of the main effects of M3 receptor ligand
C1213 on endothelial signaling pathways involved in pulmonary
vasodilation and pulmonary arterial hypertension.
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2016 | Vol. 4 | Iss. 24 | e13069
Page 7
M. Ahmed et al. Effects of M3R Ligand C1213 in PH Models
hypoxic pulmonary hypertension. Am. J. Physiol. Heart
Circ. Physiol. 292:H2316–H2323.
Harvey, R. D. 2012. Muscarinic receptor agonists and
antagonists: effects on cardiovascular function. Handb. Exp.
Pharmacol. 208:299–316.
Kolluru, G. K., J. H. Siamwala, and S. Chatterjee. 2010. eNOS
phosphorylation in health and disease. Biochimie 92:1186–
1198.
Krump-Konvalinkova, V., F. Bittinger, R. E. Unger, K. Peters,
H. A. Lehr, and C. J. Kirkpatrick. 2001. Generation of
human pulmonary microvascular endothelial cell lines. Lab.
Invest. 81:1717–1727.
Kysela, S., and J. Torok. 2000. Contemporary activation of
different endothelial receptors accounts for a reserve
mechanism of nitric oxide-mediated relaxation. Physiol. Res.
49:115–122.
Lakshminrusimha, S., J. A. Russell, S. Wedgwood, S. F.
Gugino, J. A. Kazzaz, J. M. Davis, et al. 2006. Superoxide
dismutase improves oxygenation and reduces oxidation in
neonatal pulmonary hypertension. Am. J. Respir. Crit. Care
Med. 174:1370–1377.
Lakshminrusimha, S., B. Mathew, and C. L. Leach. 2016a.
Pharmacologic strategies in neonatal pulmonary
hypertension other than nitric oxide. Semin. Perinatol.
40:160–173.
Lakshminrusimha, S., G. G. Konduri, and R. H. Steinhorn.
2016b. Considerations in the management of hypoxemic
respiratory failure and persistent pulmonary hypertension in
term and late preterm neonates. J. Perinatol. 36(Suppl 2):
S12–S19.
Leopold, J. A., and B. A. Maron. 2016. Molecular Mechanisms
of Pulmonary Vascular Remodeling in Pulmonary Arterial
Hypertension. Int. J. Mol. Sci. 17:1–14.
Morin, F. C. 3rd. 1989. Ligating the ductus arteriosus before
birth causes persistent pulmonary hypertension in the
newborn lamb. Pediatr. Res. 25:245–250.
Orii, R., Y. Sugawara, S. Sawamura, and Y. Yamada. 2010. M
(3)muscarinic receptors mediate acetylcholine-induced
pulmonary vasodilation in pulmonary hypertension. Biosci.
Trends 4:260–266.
Quillon, A., B. Fromy, and R. Debret. 2015. Endothelium
microenvironment sensing leading to nitric oxide mediated
vasodilation: a review of nervous and biomechanical signals.
Nitric Oxide 45:20–26.
Tonelli, A. R., S. Haserodt, M. Aytekin, and R. A. Dweik.
2013. Nitric oxide deficiency in pulmonary hypertension:
Pathobiology and implications for therapy. Pulm. Circ.
3:20–30.
Walch, L., X. Norel, B. Leconte, J. P. Gascard, and C. Brink.
1999. Cholinergic control of human and animal pulmonary
vascular tone. Therapie 54:99–102.
Walch, L., C. Brink, and X. Norel. 2001. The muscarinic
receptor subtypes in human blood vessels. Therapie
56:223–226.
2016 | Vol. 4 | Iss. 24 | e13069
Page 8
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Effects of M3R Ligand C1213 in PH Models M. Ahmed et al.
